The Banerhuang Tablets Veterinary Grade API is a non-sterile, multi-component botanical extract powder supplied for further processing into tablets, capsules, granules, powders, injectable solutions, oral solutions, and medicated feed premixes. Procurement documentation identifies the material by the model designation Banerhuang Tablets Veterinary Grade API; route-specific grades are denoted by vendor suffix codes BHT-API-VG/O for oral solid processing, BHT-API-VG/I for injectable preparation, and BHT-API-VG/P for premix adsorption. No globally harmonized model or monograph code exists across all target species or jurisdictions; lot release therefore requires a route-specific certificate of analysis generated under the supplier’s quality system. The API is characterized by HPLC-DAD on a C18 column (250 mm × 4.6 mm, 5 µm) with 0.1% phosphoric acid/acetonitrile gradient elution, injection volume 10 µL, column temperature 30 °C, flow rate 1.0 mL/min, and detection at 254 nm with reference wavelength 320 nm. Identification is based on retention-time correspondence to an in-house reference chromatogram rather than on a single infrared absorption spectrum. System suitability requires theoretical plates ≥5000 for the marker peak and tailing factor 0.95–1.50. Typical release data show marker-compound assay of 95.0–105.0% of label claim, loss on drying ≤5.0%, heavy metals ≤20 ppm, total aerobic microbial count ≤1000 CFU/g, and bacterial endotoxin <0.5 EU/mg for injectable grade. The product is not a single chemical entity, so its specifications are not interchangeable with a pure synthetic API monograph.

Which Release Parameters and Pharmacopoeial References Apply Across Route-Specific Grades?

The release profile is subdivided by intended formulation route. The oral solid grade is released against the core parameters listed in Table 1. The injectable grade is additionally tested for bacterial endotoxins and sub-visible particulates. The premix grade is released with blend uniformity and carrier adsorption tests. Because the product is a botanical matrix, the chromatographic fingerprint is more discriminatory than any single assay value. Lot-to-lot variation in the marker assay is controlled below 3.5% relative standard deviation. Residual solvents are controlled according to VICH GL18; the sum of Class 2 solvents is limited to ≤0.1%. Heavy metals testing follows Ph. Eur. 2.4.8, but species-specific regulatory submissions may also require arsenic, cadmium, lead, and mercury individually. The oral solid grade is not required to meet injectable endotoxin limits; only material released as BHT-API-VG/I is assigned the <0.5 EU/mg criterion. Test methods used for release data intended for marketing authorization should be conducted under ISO/IEC 17025-accredited conditions.

Particle size distribution and its effect on direct compression and granulation

In direct compression, the spray-dried oral grade with D90 ≤75 µm by laser diffraction per ISO 13320:2020 provides acceptable blending uniformity only when combined with microcrystalline cellulose PH102 and a disintegrant. On a 16-station B-tooling rotary tablet press at 18–24 kN compression force, a formulation containing 35 wt% API, 45 wt% MCC PH102, 15 wt% lactose monohydrate, and 5 wt% crospovidone produced tablets with hardness 8–12 kp, friability <0.5% per USP <1216>, and disintegration 4–7 min in purified water at 37 ± 2 °C per USP <701>. Tablet weight variation at 60,000 tablets/h remained within ±3.0%. Lamination occurred when granule moisture exceeded 3.5% w/w; pre-drying at 60 °C for 2 h in a forced-air tray dryer restored compressibility. In high-shear wet granulation using a Gral 10 L mixer and 6% w/w povidone K30 solution, the torque plateau was reached after 7–9 min at an impeller speed of 180 rpm; resulting granules exhibited Hausner ratio 1.15–1.25 and Carr’s compressibility index 13–20%. Coarser spray-dried material with D90 120–180 µm is acceptable for capsule filling but may segregate in low-shear twin-shell blending when fines content exceeds 25%; blend uniformity RSD above 8% was observed in 3 of 10 pilot batches until geometric dilution was adopted. Dry granulation by slugging on a 14-station tablet press at 20 kN followed by 1.25 mm screen milling produced granules with D50 300–400 µm. Direct compression ejection force was 400–600 N; lubrication with magnesium stearate above 1.0% w/w reduced hardness by 15–20% because of hydrophobic film formation. Tablets containing the API at 50 wt% required precompression force of 5 kN to avoid capping at main compression above 22 kN.

When Injectable Grade Material Is Required, Endotoxin and Sterility Constraints Apply

Injectable solutions are commonly prepared at 10 mg/mL in water for injection adjusted to pH 6.8–7.2 with 0.1 N sodium hydroxide or hydrochloric acid. The solution is filtered through a 0.22 µm polyethersulfone membrane and terminally sterilized at 121 °C for 15 min. Aseptic filling alone is not recommended because the botanical matrix can contain heat-resistant spores; terminal sterilization is the preferred process when the formulation allows. Sterility testing is performed by membrane filtration per Ph. Eur. 2.6.1 with incubation at 30–35 °C for 14 days. The injectable grade is released with bacterial endotoxin <0.5 EU/mg per Ph. Eur. 2.6.14 and sub-visible particulate matter limits of ≤6000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm per Ph. Eur. 2.9.19 when filled in 100 mL vials. pH drift below 5.0 during buffer preparation accelerates precipitation of polyphenolic constituents; pH above 8.5 accelerates oxidative darkening. Degradation studies at 121 °C for 30 min showed marker recovery 98.0–101.0% at pH 6.5–7.5, but recovery fell below 95% at pH 5.0 because of precipitation. Published data for this specific botanical matrix in oil-in-water injectable emulsions is limited; no recommendation is made for emulsion-based parenteral formulations without forced degradation and droplet-size stability data.

In veterinary feed premix operations, the oral or premix grade is adsorbed onto a corncob or rice-hull carrier at 5 wt% in a horizontal ribbon mixer operated at 40 rpm for 15 min. HPLC blend uniformity showed RSD <5.0% after 15 min, meeting the 2.5% acceptance threshold for low-dose medicated premixes used in several jurisdictions. The product should not be blended with alkaline mineral sources such as calcium carbonate above 10% of the premix when storage exceeds 60 days at 40 °C/75% RH; under these conditions, extractable polyphenols darken and marker recovery decreases by 4–6%. For complete feed, the API may be incorporated at 500 g/tonne followed by pelleting at 75 °C for 20 s; marker recovery after pelleting was 96.5–99.0% in pilot extrusion trials. Published data for this specific botanical matrix in expanded extruded feed is limited. Capsule filling with lactose monohydrate and 1% magnesium stearate achieved weight variation ≤3.0% at 60,000 capsules/h on an automatic dosator machine. Solutions for oral dosing are prepared by dissolving the oral-grade powder in purified water at 2 mg/mL with gentle heating to 40 °C; sodium metabisulfite at 0.1% w/v may be used as an antioxidant, but the sulfite adduct should be monitored by HPLC because marker-area loss after 24 h can exceed 5%. Avoid combining the product with ferric salts, strong oxidizing agents, and quaternary ammonium preservatives due to precipitation and oxidative incompatibility. The product is soluble in aqueous systems over a pH range of 3.0–7.5 at 2 mg/mL, but solubility decreases sharply at pH >8.0 due to ionization of phenolic groups. Oral solutions prepared with municipal water above pH 8.0 should be buffered with 0.05 M citrate buffer.

Differences from Single-Marker Botanical Powders and Synthetic Small-Molecule Veterinary APIs

Compared with unstandardized single-marker botanical powders, Banerhuang Tablets Veterinary Grade API is differentiated by its route-specific release grades, its defined marker-assay range of 95.0–105.0%, and its batch-to-batch marker RSD controlled below 3.5%. Unstandardized botanical lots often vary by 20–40% in marker content, which shifts the API-to-excipient ratio and can invalidate a validated tableting or premix process. Compared with synthetic small-molecule veterinary APIs, the product has a broader aqueous solubility profile but a narrower dry-heat tolerance; exposure to dry heat above 80 °C for more than 24 h leads to darkening and marker-area loss. The product has no single melting point, so melting-range identity tests are not applicable. Its multi-component matrix contains several chromatographic peaks rather than a single active entity; therefore, the supplier’s HPLC fingerprint method should be used in place of a single-analyte assay for batch release. The product also differs from synthetic APIs in its light sensitivity; exposure to UV light at 365 nm for 48 h reduced marker content by 6–8%, so amber glass or opaque high-density polyethylene containers are required for liquid dosage forms. The multi-component matrix may reduce the risk of single-target resistance selection in some veterinary applications, but this statement is not regulatory evidence of clinical efficacy; target animal safety and field efficacy must be established under the applicable veterinary drug approval pathway.

At storage conditions below 25 °C and 60% RH, the unopened bulk powder is stable for 24 months from the date of manufacture in double polyethylene bags inside a fiber drum. Once opened, the material should be used within 30 days when stored under nitrogen; otherwise, moisture content may exceed 5.0% and compressibility index may rise above 20%, affecting tableting weight control. The API is for veterinary use only; no human pharmacopoeial monograph is assigned in all regions. Incompatibilities include strong oxidizing agents, ferric salts, alkaline earth-metal hydroxides, and amine-containing disintegrants at wet granulation temperatures above 55 °C. Residual moisture above 3.5% w/w should be avoided before dry granulation or compression. Published data for this specific configuration in pressurized metered-dose inhalation is limited; no recommendation is made for aerosolized delivery.